# PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia

> **NCT01854944** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Brexpiprazole 1mg to 4mg

## Key facts

- **NCT ID:** NCT01854944
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854944, "PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01854944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*